Active	Status	Sponsor type	Region	Phase	Filter
10 Active 0 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

10 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Matsuoka, Osamu
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
ACHIEVE-1, NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone	Active, not recruiting	3	520	Japan, US, RoW	Orforglipron, LY3502970, Placebo	Eli Lilly and Company	Type 2 Diabetes	04/25	04/25
ATTAIN-J, NCT05931380: A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease	Active, not recruiting	3	236	Japan	Orforglipron, Placebo	Eli Lilly and Company	Obesity	06/25	07/25
ACHIEVE-J, NCT06010004: A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes	Active, not recruiting	3	399	Japan	Orforglipron, LY3502970	Eli Lilly and Company	Type 2 Diabetes	06/25	06/25
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities	Active, not recruiting	3	3000	Europe, Japan, US, RoW	Orforglipron, LY3502970, Placebo	Eli Lilly and Company	Obesity, Overweight, Overweight or Obesity	09/25	09/27
NCT05026866: A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)	Recruiting	3	2600	Japan, US	Donanemab, LY3002813, Placebo	Eli Lilly and Company	Alzheimer Disease	11/27	11/27
NCT05565742: A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]	Active, not recruiting	2	216	Europe, Japan, US, RoW	LY3819469, Placebo	Eli Lilly and Company	Lipoprotein Disorder	10/23	10/24
PROLONG-ANG3, NCT05256654: A Study of LY3561774 in Participants With Mixed Dyslipidemia	Active, not recruiting	2	175	Europe, Canada, Japan, US, RoW	LY3561774, Placebo	Eli Lilly and Company	Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia	03/24	06/24
NCT06074562: A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain	Recruiting	2	410	Europe, Japan, US, RoW	LY3556050, Placebo	Eli Lilly and Company	Diabetic Peripheral Neuropathy	01/25	01/25
NEPTUNE-17, NCT05838755: A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain	Recruiting	2	240	Europe, Canada, Japan, US, RoW	GSK3858279, Placebo	GlaxoSmithKline	Pain	03/25	06/25